some phase ii clinical trials have been carried out, but preliminary results indicate that primary study endpoints were not met and that opicinumab exhibits unexpected dose-response relationships. further studies were planned by the company, as opicinumab still was deemed to show potential for clinical efficacy in the treatment of ms.